Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone

Gianluca Tornese, Elena Faleschini, Lorenza Matarazzo, Cristina Bibalo, Giulio Andrea Zanazzo, Marco Rabusin, Giorgio Tonini, Floriana Zennaro, Alessandro Ventura

Research output: Contribution to journalArticle

Abstract

Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalNeuropediatrics
Volume46
Issue number2
DOIs
Publication statusPublished - Feb 4 2015

Fingerprint

Neurofibromatosis 1
Human Growth Hormone
Growth Hormone
Neoplasm Metastasis
Recurrence
Magnetic Resonance Imaging
Cerebellum
Brain Neoplasms
Brain Stem
Typical Teratoid Rhabdoid Tumor
Atypical Teratoid Tumor
Radiotherapy
Therapeutics
Drug Therapy

Keywords

  • AT/RT
  • brain tumor
  • NF1
  • recurrence
  • rhGH

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone. / Tornese, Gianluca; Faleschini, Elena; Matarazzo, Lorenza; Bibalo, Cristina; Zanazzo, Giulio Andrea; Rabusin, Marco; Tonini, Giorgio; Zennaro, Floriana; Ventura, Alessandro.

In: Neuropediatrics, Vol. 46, No. 2, 04.02.2015, p. 126-129.

Research output: Contribution to journalArticle

@article{2ea2fd80037c4e349bae2f349c10dba7,
title = "Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone",
abstract = "Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.",
keywords = "AT/RT, brain tumor, NF1, recurrence, rhGH",
author = "Gianluca Tornese and Elena Faleschini and Lorenza Matarazzo and Cristina Bibalo and Zanazzo, {Giulio Andrea} and Marco Rabusin and Giorgio Tonini and Floriana Zennaro and Alessandro Ventura",
year = "2015",
month = "2",
day = "4",
doi = "10.1055/s-0034-1393706",
language = "English",
volume = "46",
pages = "126--129",
journal = "Neuropediatrics",
issn = "0174-304X",
publisher = "Hippokrates Verlag GmbH",
number = "2",

}

TY - JOUR

T1 - Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone

AU - Tornese, Gianluca

AU - Faleschini, Elena

AU - Matarazzo, Lorenza

AU - Bibalo, Cristina

AU - Zanazzo, Giulio Andrea

AU - Rabusin, Marco

AU - Tonini, Giorgio

AU - Zennaro, Floriana

AU - Ventura, Alessandro

PY - 2015/2/4

Y1 - 2015/2/4

N2 - Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

AB - Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

KW - AT/RT

KW - brain tumor

KW - NF1

KW - recurrence

KW - rhGH

UR - http://www.scopus.com/inward/record.url?scp=84964267443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964267443&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1393706

DO - 10.1055/s-0034-1393706

M3 - Article

C2 - 25625887

AN - SCOPUS:84964267443

VL - 46

SP - 126

EP - 129

JO - Neuropediatrics

JF - Neuropediatrics

SN - 0174-304X

IS - 2

ER -